Literature DB >> 1860718

Plasma immunoreactive endothelin-1 in experimental malignant hypertension.

M Kohno1, K Murakawa, T Horio, K Yokokawa, K Yasunari, T Fukui, T Takeda.   

Abstract

We measured plasma concentrations of immunoreactive endothelin-1 (irET-1) in the prehypertensive and hypertensive phases in spontaneously hypertensive rats (SHR) and in malignant hypertension caused by deoxycorticosterone acetate (DOCA)-salt administration in SHR. We also measured concentrations of this peptide in another model of malignant hypertension, the two-kidney, one clip (2K1C) renovascular hypertensive rats chronically given caffeine. Plasma irET-1 concentrations in young (6-week-old) and mature (18-week-old) SHR did not differ from those of age-matched Wistar-Kyoto (WKY) rats. Four weeks of treatment with DOCA-salt increased blood pressure, blood urea nitrogen, serum creatinine, and plasma irET-1 in SHR but not in WKY rats. Eight weeks of DOCA-salt treatment further increased these values in SHR. Plasma irET-1 concentrations were not increased in the 2K1C rats. Six weeks of caffeine administration increased blood pressure, blood urea nitrogen, serum creatinine, plasma renin activity, and plasma irET-1 in the 2K1C rats but not in the sham-operated rats. High-performance liquid chromatographic profiles of plasma extracts pooled from these rats with malignant hypertension showed that a major component of irET-1 eluted in the position of synthetic ET-1 (1-21). Furthermore, acute hypertension induced by angiotensin II or phenylephrine did not affect the plasma irET-1 concentration in rats. The results suggested that the plasma ET-1 concentration is increased in rat models of malignant hypertension and that the high blood pressure itself is not the main factor involved in the increase of plasma ET-1.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860718     DOI: 10.1161/01.hyp.18.1.93

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Modeling and docking the endothelin G-protein-coupled receptor.

Authors:  A J Orry; B A Wallace
Journal:  Biophys J       Date:  2000-12       Impact factor: 4.033

Review 2.  Endothelial dysfunction and hypertension.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 3.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

4.  Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats.

Authors:  V Niranjan; S Télémaque; D deWit; R D Gerard; M Yanagisawa
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

5.  Pyk2 mediates increased adrenergic contractile responses in arteries from DOCA-salt mice - VASOACTIVE PEPTIDE SYMPOSIUM.

Authors:  Fernanda R C Giachini; Fernando S Carneiro; Victor V Lima; Zidonia N Carneiro; Maria Helena C Carvalho; Zuleica B Fortes; R Clinton Webb; Rita C Tostes
Journal:  J Am Soc Hypertens       Date:  2008 Nov-Dec

6.  Blood pressure regulates platelet-derived growth factor A-chain gene expression in vascular smooth muscle cells in vivo. An autocrine mechanism promoting hypertensive vascular hypertrophy.

Authors:  N Negoro; Y Kanayama; M Haraguchi; N Umetani; M Nishimura; Y Konishi; J Iwai; M Okamura; T Inoue; T Takeda
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

7.  Role of endothelin-1 and the ETA receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension.

Authors:  K Fujita; Y Matsumura; S Kita; Y Miyazaki; K Hisaki; M Takaoka; S Morimoto
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

8.  Downregulation of Renal G Protein-Coupled Receptor Kinase Type 4 Expression via Ultrasound-Targeted Microbubble Destruction Lowers Blood Pressure in Spontaneously Hypertensive Rats.

Authors:  Hefei Huang; Xiaolong Li; Shuo Zheng; Yue Chen; Caiyu Chen; Jialiang Wang; Haipeng Tong; Lin Zhou; Jian Yang; Chunyu Zeng
Journal:  J Am Heart Assoc       Date:  2016-10-06       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.